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Abstract
To investigate the suppressive effect of human recombinant TIMP-1 (rh-TIMP-1) on tumor
proliferation using an in vivo xenograft system, HT29 was suspended in 0.1 ml phosphate buffered
saline (PBS) and then subcutaneously injected in the back of female mice (BALB/C nu/nu). The
mice were divided into 2 groups an and the tumor diameter was measured after rh-TIMP-1 (2
mg/kg) (rh-TIMP-1 group) or PBS (control group) was administered injections according to the
following schedules. Schedule 1 : Beginning 2 weeks after the subcutaneous injection of HT29,
an intraperitoneal injection of rh-TIMP-1 or PBS were performed twice a day (every 12 h) for
14 consecutive days. Schedule 2 : Beginning 1 week after the subcutaneous injection of HT29,
an intraperitoneal injection was performed twice a day for 14 consecutive days. Schedule 3 :
Intraperitoneal injections were started simultaneously with the subcutaneous injection of HT29,
and then performed twice a day for 21 consecutive days. The mice were sacrificed and the tumors
extirpated for immunohistochemical investigation. In addition, gelatin zymography and a cell
proliferation assay were performed. With Schedule 1, the changes in the tumor diameter in the
rh-TIMP-1 group followed the same course as those in the control group, and no suppressive effect
on tumor proliferation was observed. However, with Schedule 3, a remarkable suppressive effect
was observed throughout the treatment period. In immunostaining, more cases negative for MMP-
9 were observed in the rh-TIMP-1 group than in the control group. Cases negative for CD34 were
significantly more observed in the rh-TIMP-1 group than in the control group with Schedule 3.
All of the results were obtained through the suppressive effect of rh-TIMP-1 on angiogenesis.
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n the processes of proliferation and invasion of 
cancer cells,  disruption of the extracellular 
matrix (ECM) is essential [1].  Matrix metallopro-
teinases (MMPs) [2] play a central role in these pro-
cesses,  and are closely involved in the disruption of 
the basal membrane which is one of the processes of 
hematogenous metastasis [3].  It is thought that a 
part of the hematogenous metastasis process can be 
I
To investigate the suppressive eﬀ ect of human recombinant TIMP-1 (rh-TIMP-1) on tumor prolifera-
tion using an in vivo xenograft system,  HT29 was suspended in 0.1 ml phosphate buﬀ ered saline (PBS) 
and then subcutaneously injected in the back of female mice (BALB/C nu/nu).  The mice were divided 
into 2 groups an and the tumor diameter was measured after rh-TIMP-1 (2 mg/kg) (rh-TIMP-1 group) 
or PBS (control group) was administered injections according to the following schedules.  Schedule 
1 : Beginning 2 weeks after the subcutaneous injection of HT29,  an intraperitoneal injection of 
rh-TIMP-1 or PBS were performed twice a day (every 12 h) for 14 consecutive days.  Schedule 
2 : Beginning 1 week after the subcutaneous injection of HT29,  an intraperitoneal injection was per-
formed twice a day for 14 consecutive days.  Schedule 3 : Intraperitoneal injections were started 
simultaneously with the subcutaneous injection of HT29,  and then performed twice a day for 21 con-
secutive days.  The mice were sacriﬁ ced and the tumors extirpated for immunohistochemical investi-
gation.  In addition,  gelatin zymography and a cell proliferation assay were performed.  With 
Schedule 1,  the changes in the tumor diameter in the rh-TIMP-1 group followed the same course as 
those in the control group,  and no suppressive eﬀ ect on tumor proliferation was observed.  However, 
with Schedule 3,  a remarkable suppressive eﬀ ect was observed throughout the treatment period.  In 
immunostaining,  more cases negative for MMP-9 were observed in the rh-TIMP-1 group than in the 
control group.  Cases negative for CD34 were signiﬁ cantly more observed in the rh-TIMP-1 group 
than in the control group with Schedule 3.  All of the results were obtained through the suppressive 
eﬀ ect of rh-TIMP-1 on angiogenesis.
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controlled by suppressing the activity of MMPs that 
have strong collagenolytic activity toward type IV 
collagen,  a primary component of the basal mem-
brane.  It is thought that a part of the hematogenous 
metastasis process can be controlled by suppressing 
the activity of MMPs,  which have strong collageno-
lytic activity toward type IV collagen,  a primary 
component of the basal membrane.  Numerous studies 
have investigated the suppressive eﬀ ect of tissue 
inhibitors of metalloproteinases (TIMPs),  which are 
speciﬁ c inhibitors of MMP,  on tumor proliferation 
and metastasis [4].  Particularly in many studies 
using colon cancer cell lines or tissue specimens,  the 
quantitative balance of MMPs and TIMPs in the 
local tumor is reported to inﬂ uence the tumor prolif-
eration and invasion processes [5].  Some investiga-
tors have reported an inhibitory eﬀ ect of TIMPs on 
angiogenesis [6],  as well as a suppressive eﬀ ect on 
tumor proliferation.  However,  in many of these stud-
ies,  TIMPs were excessively expressed by introduc-
ing the TIMPs gene into hosts or tumor cells,  and 
few reports have investigated the in vivo eﬀ ect of 
recombinant TIMP administration [7].  In the pres-
ent study,  an in vivo treatment model was prepared 
using a human colon cancer cell line,  HT29.  The 
suppressive eﬀ ect of recombinant TIMP-1,  which 
had a strong inhibitory activity toward MMP-9,  on 
tumor proliferation was investigated after multiple 
intraperitoneal injections of rh-TIMP-1.
Materials and Methods
　　 Preparation of treatment model.　 A treat-
ment model was prepared by the following methods. 
All animals experiments were performed according 
to the Guidelines for Animal Experiments of 
Okayama University Medical School.
　　(1) Preparation of cell culture and cell 
suspension.　 A monolayer culture of the cell line 
HT29 (ATCC,  Manassas,  VA,  USA) derived from 
human colon cancer was performed in a ﬂ ask with 
McCoy’s 5A medium (Invitrogen,  CA,  USA) with the 
addition of 10ｵ FBS (Invitrogen,  Carlsbad,  CA, 
USA),  in an incubator at a 37 °C,  5ｵ CO2 atmo-
sphere.  The medium was completely aspirated when 
the cells became 90ｵ conﬂ uent,  and 0.05ｵ trypsin/
EDTA (Invitrogen,  Carlsbad,  CA,  USA) was added. 
The cells were peeled oﬀ  5 min later,  and suspended 
again in medium to prepare the cell suspension.  Part 
of the suspension was stained with 0.2ｵ trypan blue 
(Invitrogen,  Carlsbad,  CA,  USA),  and the number 
of cells was counted using a cell counting slide.  The 
cells were suspended in PBS (－) so that the number 
of viable cells became 1 × 107/ml.
　　(2) Preparation of treatment model.　 To the 
bilateral back of 6ﾝ4 week-old female nude mice 
(BALB/c-nu/nu,  body weight ; about 20 g,  Clea 
Japan,  Osaka,  Japan),  0.1 ml (＝ 2 × 106) of HT29 
cell suspension was subcutaneously injected using a 
29G needle.  The mice were divided into the follow-
ing 2 groups an rh-TIMP-1 group of 10 mice that 
received intraperitoneal injections of 2 mg/kg human 
recombinant TIMP-1 (rh-TIMP-1,  Daiichi Fine 
Chemical,  Toyama,  Japan) and a control group of 10 
mice that received 0.1 ml PBS (－).  The time course 
of the major and minor axis of the subcutaneous 
tumor in the back were measured in both groups. 
The tumor volume was obtained by using the follow-
ing approximation formula : 
Tumor volume ≒ π/6 × (the major axis of 
　tumor) × (the minor axis of tumor)2
In addition,  the body weight of the mice on the last 
dosing day in both groups was measured to evaluate 
the side eﬀ ects of rh-TIMP-1.
　　(3) Treatment schedule.　 The intraperitoneal 
injections of the rh-TIMP-1 (rh-TIMP-1 group) or 
PBS (control group) mice were performed according 
to the following schedule.
Schedule 1 : Beginning 15 days after the subcutane-
ous injection of HT29,  an intraperitoneal injec-
tion of rh-TIMP-1 or PBS was performed twice a 
day (every 12 h) for 14 consecutive days.
Schedule 2 : Beginning 8 days after the subcutaneous 
injection of HT29,  an intraperitoneal injection of 
rh-TIMP-1 or PBS was performed twice a day 
for 14 consecutive days.
Schedule 3 : An intraperitoneal injection of rh-
TIMP-1 or PBS was started simultaneously with 
the subcutaneous injection of HT29,  and per-
formed twice a day there after for 21 consecutive 
days.
　　Investigation of MMP secretory capacity of 
cultured cells.　 To investigate the gelatinolytic 
ability of HT29,  the MMP secretory capacity was 
observed through gelatin zymography.  The inﬂ uence 
of rh-TIMP-1 on gelatinolytic activity was also evalu-
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ated.
　　(1) Sample preparation.　 HT29 (1 × 105) was 
suspended in McCoy’s 5A medium (serum free) in 2 
dishes for cell culture (60 mm in diameter). 
rh-TIMP-1 (500 ng/ml) was added to one dish only. 
The dishes with and without rh-TIMP-1 were incu-
bated at a 37 °C,  5ｵ CO2 atmosphere for 24 h. 
Both the dish with rh-TIMP-1 and the dish without it 
were incubated at a 37 °C,  5ｵ CO2 atmosphere for 
24 h.  The medium in the dishes was completely col-
lected,  and concentrated using an Amicon Ultra cen-
trifuged ﬁ lter device (Millipore,  Billerica,  MA, 
USA).  Gelatin zymography was then performed 
using the concentrated medium as a sample.
　　(2) Gelatin zymography.　 In gelatin zymogra-
phy,  the enzymatic activity is evaluated based on the 
gelatin resolution in gel after SDS-Poly Acrylamide 
Gel Electrophoresis (PAGE).  This method is a supe-
rior one for evaluating MMP-2 (gelatinase A) and 
MMP-9 (gelatinase B).  We performed gelatin zymog-
raphy using a Gelatinzymo Electrophoresis Kit (Yagai, 
Yamagata,  Japan) according to the methods proposed 
by Heussen et al.  [8].
　　First,  10 μl of the sample was homogenized by 
the buﬀ er (10 mM Tris-HCL,  PH6.8,  20ｵ glycerol, 
2ｵ SDS,  0.1 bromophenol blue),  and SDS-PAGE 
(at 10 mA for 10 min and 20 mA for 80 min) was per-
formed with 10ｵ polyacryl amidegel in the addition 
of 0.1ｵ gelatin.  After the gel plate was shaken for 
30 min twice with 2ｵ triton-X100,  it was reacted 
with enzyme reaction liquid (50 mM Tris-HCL, 
150 mM Nacl,  10 mM CaCl2,  0.02ｵ NaN3) at 37 °C 
for 36 h.  After completion of the enzyme reaction, 
the protein in the gel plate was stained with a stain-
ing ﬂ uid (30ｵ ethanol,  10ｵ acetate acid,  0.3ｵ tri-
pan blue) and decolored with a decoloring solution (10
ｵ acetate acid,  30ｵ methanol in distilled water). 
The gel electrophoresis fragment pattern was 
observed to evaluate the gelatinolytic activity of 
HT29.
Immunohistochemical investigation.
　　(1) Preparation of materials.　 On the last dos-
ing day of rh-TIMP-1 in Schedules 1,  2 and 3,  the 
mice were sacriﬁ ced using 500 mg/kg pentobarbital 
sodium (Dainippon Pharmaceutical,  Osaka,  Japan), 
and the tumor was extirpated under clean conditions. 
The tumor was ﬁ xed with periodate-lysine-parafor-
maldehyde (PLP) ﬁ xing solution at 4 °C for 24 h, 
and paraﬃ  n embedding was then performed to make a 
tissue block.  The block was sliced to a thickness of 
2.5 μm,  and was adhered to the MAS-coated slide to 
prepare sections.
　　(2) Immunohistochemical staining.　 Immuno-
staining of the paraﬃ  n sections was performed 
according to the method proposed by Sannino et al. 
[9].  Brieﬂ y,  deparaﬃ  nization of the sections was 
performed using xylene and ethanol,  and the antigen 
activating treatment using citric acid buﬀ er (Target 
Retrieval Solution : DAKO,  Glostrup,  Denmark) 
was performed by heating in a microwave at 500W. 
Blocking of the endogenous peroxydase activities was 
then performed using 0.3ｵ H2O2 solution.  Generally, 
after blocking,  tumor sections are reacted with anti-
mouse monoclonal antibodies.  However,  since we had 
diﬃ  culty performing background staining due to a 
reaction by the second antibody with the endogenous 
mouse immunoglobulin,  we performed the subsequent 
immunostaining process by applying the Polymer 
immunocomplex (PIC) method reported by Fukuda et 
al.  [10].  First,  a polymer immunocomplex was 
formed by mixing a primary antibody (Anti-hMMP-2 
puriﬁ ed IgG : Daiichi Fine Chemical,  Takaoka, 
Japan,  Anti-hMMP-9 puriﬁ ed IgG : Santa Cruz 
Biotechnology,  Santa Cruz,  Ca,  USA,  Anti-CD34 
puriﬁ ed IgG : Hycult Biotechnology,  Uden, 
Netherlands) with a second antibody (ENVISION＋ 
for mouse : DAKO,  Glostrup,  Denmark).  Normal 
mouse serum was added to the immunocomplex to 
block polyclonal antibodies to mouse immunoglobulin 
from binding to the second antibody.  Subsequently, 
the immunocomplex was diluted 100-fold with anti-
body dilution (DAKO,  Glostrup,  Denmark).  Drops 
of this solution were put on the tissues,  and the tis-
sues were reacted at 37 °C for 60 min.  Matrix stain-
ing with 0.02ｵ diaminobenzidine tetrahydrochloride 
(DAB) solution and nuclear staining with Mayer’s 
hematoxylene were then performed.  Finally,  dehy-
dration and encapsulation using ethanol and xylene 
were performed.
　　(3) Staining evaluation.　 The immunostained 
tissues were evaluated according to the following cri-
teria.
　　MMP-2,  -9 : Five arbitrary visual ﬁ elds of prepa-
ration were microscopically visualized at 200-fold 
magniﬁ cation.  When the number of visual ﬁ elds in 
which color development was observed in not less 
259Suppression Eﬀ ects of rh-TIMP-1 in VivoOctober 2006
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than 10ｵ of the cancer cells was 3 or more in one 
preparation,  the staining result was evaluated as 
“positive”.  When the number of visual ﬁ elds in which 
color development was observed in not less than 10ｵ 
of the cancer cells was 2 or less in one preparation, 
the staining result was evaluated as “negative”.
　　CD34 : The preparation was microscopically visu-
alized at a 20-fold magniﬁ cation to ﬁ nd the high-den-
sity areas.  These areas were observed again at 
200-fold magniﬁ cation,  and the number of stained 
lesions inside the lumen were counted.  The same 
observations were performed at 5 arbitrary visual 
ﬁ elds,  and the mean values were recorded.  These 
values were regarded as the microvessel count (MVC), 
and compared between the rh-TIMP-1 and Control 
Groups.
　　Cell proliferation assay.　 HT29 of the 
1 × 105/well was placed in a 96-well cell culture 
plate,  and incubated at a 37 °C,  5ｵ CO2 atmosphere 
for 72 h in the presence (500,  250,  100,  50 and 
10 ng/ml) and absence (0 ng/ml) of rh-TIMP-1. 
Subsequently,  20 μl of Cell Titer 96 Aqueous One 
Solution Reagent (Promega,  Madison,  MI,  USA), 
which is a reagent containing tetrazolium compound 
260 Acta Med.  Okayama　Vol.  60,  No.  5Ohtani et al.
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Fig. 1　　Subsequent diﬀ erences in tumor diameter among various treatment schedules with rh-TIMP-1 were investigated.  (A) With 
Schedule 1,  there was no diﬀ erence in tumor diameter between [the] rh-TIMP-1 and control groups.  (B) With Schedule 2,  the eﬀ ect of 
rh-TIMP-1 was transient.  (C) However,  with Schedule 3,  a signiﬁ cant diﬀ erence in tumor diameter between the rh-TIMP-1 and control 
groups was continuously observed (# : p ＜ 0.05,  ＊ : p ＜ 0.01 vs.  control,  ▼ : day when the intraperitoneal administration of rh-TIMP-1 
was started).  (D) The conditions of the subcutaneous tumor 21 days after the start of Schedule 3 treatment (white circle) are shown.
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(MTS),  was added to each well.  After incubation at 
37 °C,  5ｵ CO2 for 2 h,  the absorbance at 490 nm 
was measured using a micro plate reader.
　　Statistical analysis.　 All statistical analyses 
were performed using the chi-square test or 
Student-t test.  P values of less than 0.05 were con-
sidered statistically signiﬁ cant.
Results
　　Changes of tumor volume and body weight 
with each treatment schedule.　 When HT29 
was subcutaneously injected to the treatment model, 
a subcutaneous tumor visible to the naked eye formed 
in approximately 1 week.  The tumor was observed in 
all the mice receiving the HT29 subcutaneous injec-
tion.  With Schedule 1,  there was no diﬀ erence in 
tumor diameter between the rh-TIMP-1 and control 
groups during the entire treatment period.  With 
Schedule 2,  a signiﬁ cant diﬀ erence (p ＜ 0.05) 
between the rh-TIMP-1 and control groups was 
observed during the initial 10 days of rh-TIMP 
administration,  but subsequently the tumor diameters 
in the rh-TIMP-1 group approximated those in the 
control group.  With Schedule 3,  a signiﬁ cant sup-
pression of tumor proliferation (p ＜ 0.01) was contin-
uously observed (Fig.  1Aﾝ1D).  With all schedules, 
there were no signiﬁ cant diﬀ erences in body weight 
at the last dosing day between the control and 
rh-TIMP-1 groups (data not shown).
　　MMP secretory capacity.　 In gelatin zymogra-
phy,  ProMMP-9,  MMP-9 and MMP-2 were observed 
as clear unstained belts at 92KDa,  82KDa and 
62KDa,  respectively.  In the monoculture of HT29, 
the secretion of MMP-2 and MMP-9 was conﬁ rmed. 
In addition,  HT29 was monoculture in the rh-TIMP-1 
added medium to investigate the secretory capacity 
of MMPs,  but no changes in the gelatinolysis pattern 
were observed.  The concentrations of rh-TIMP-1 
were changed from 10 to 500 ng/ml,  but the patterns 
did not change,  indicating no concentration depen-
dence (data not shown).  This indicated that the 
rh-TIMP-1 administration had no inﬂ uence on the 
secretory capacity of MMP-2 or MMP-9 of the tumor 
cells (Fig.  2).
　　Localization and staining properties of 
MMPs evaluated by immunohistochemical 
staining.　 MMPs were stained mainly in the inter-
stitium,  although a small portion of them were 
stained in the nuclei.  MMP-2 was strongly stained in 
the lumen of the microvessels and the surrounding 
region (Fig.  3A).
　　With Schedule 1,  positive stainings for both 
MMP-2 and MMP-9 were observed in all mice of the 
rh-TIMP-1 and control groups.  With Schedule 2, 
positive stainings for MMP-2 were observed in all 
mice,  and negative stainings for MMP-9 were 
observed in approximately 20ｵ of the mice.  With 
Schedule 3,  positive stainings for MMP-2 were 
observed in all mice,  and negative stainings for 
MMP-9 were observed in approximately 55ｵ of the 
mice (Fig.  3B).
　　Evaluation of microvessels formation by 
immunohistochemical staining.　 Immunohistoc
hemical staining using CD34,  which was a speciﬁ c 
marker of vascular endothelial cells,  was performed 
to evaluate angiogenesis (Fig.  4).  Based on the 
result,  MVC was measured.  With Schedule 1 or 2, 
no signiﬁ cant diﬀ erence in MVC was observed 
between the rh-TIMP-1 and control groups.  With 
Schedule 3,  a signiﬁ cant suppression of angiogenesis 
was observed in the rh-TIMP-1 group (p ＜ 0.01 vs 
control) (Fig.  5).
　　Inﬂ uence of rh-TIMP-1 on cell proliferation 
capacity.　 A cell proliferation assay was per-
formed to investigate the inﬂ uence of rh-TIMP-1 on 
261Suppression Eﬀ ects of rh-TIMP-1 in VivoOctober 2006
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Fig. 2　　The inﬂ uence of rh-TIMP-1 administration on gelatinolytic 
activity of HT29 was investigated by gelatin zymography.  The 
activity is indicated as an achromatic white band.  There was no 
diﬀ erence in the activity between the control (TIMP-1 (－)) and 
rh-TIMP-1 (TIMP-1 (＋)) groups.
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tumor cells.  The reaction time of rh-TIMP-1 was 
changed from 24 to 72 h under the concentration of 
rh-TIMP-1,  10 ng/ml,  but the proliferation capacity 
of tumor cells did not change,  indicating no inﬂ uence 
of the reaction time (Fig.  6).  The concentrations of 
rh-TIMP-1 were changed from 50 to 500 ng/ml,  but 
the proliferation capacity did not change,  indicating 
no concentration dependence (data not shown).
Discussion
　　Several complicated steps are necessary for 
tumor cells to separate from the primary lesion,  be 
implanted in distant organs,  and form new lesions. 
The tumor cells must : 1) proliferate,  2) be inﬁ l-
trated from the primary lesion,  3) invade the vessels, 
4) reach the capillary bed of distant organs,  5) 
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Fig. 4　　Immunohistochemical staining using CD34,  which was a speciﬁ c marker of vascular endothelial cells,  was performed to 
evaluate microvessels formation.  A,  In the control group,  there were stained endothelial cells (arrow head) and a wide range of 
microvessels formation (× 200) with schedule 3 ; B,  Stained endothelial cells were rarely observed in the rh-TIMP-1 group (× 200) with 
schedule 3.  Bars in ﬁ gures indicate 25 µm.
A B
Fig. 3　　The inﬂ uence of rh-TIMP-1 administration on MMPs production was immunohistochemically investigated.  MMPs were stained 
mainly in the interstitium,  and a small portion of them were stained in the nuclei.  Regarding MMP-2,  strong stains were observed in the 
microvessels lumen and its surroundings.  When staining properties with each treatment schedule were compared among the rh-TIMP-1 
and control groups (n ＝ 10 each),  positive stainings for both MMP-2 and MMP-9 were observed in all mice in both groups with Schedule 1. 
With Schedules 2 and 3,  positive stainings for MMP-2 were observed in all mice,  and negative stainings for MMP-9 were observed in 
20% and 40% of mice,  respectively (A : MMP-2 positive case, × 200.  B : MMP-9 positive case, × 100).  Bars in ﬁ gures indicate 25 µm.
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adhere to the endocapillary cells,  6) escape from the 
vessels,  and 7) inﬁ ltrate distant organs.  These pro-
cesses include the three steps of adhesion,  degrada-
tion and movement (3-step theory of Liotta [11]). 
Among these steps,  the degradation (inﬁ ltration) of 
Type IV collagen,  which is a constituent of the basal 
membrane,  must be controlled to inhibit the inﬁ ltra-
tion and metastasis of tumor cells,  and many funda-
mental experiments to accomplish this have been per-
formed.
　　To inﬁ ltrate the surrounding tissues and metasta-
size to the distant tissues and organs through the 
capillary vessels and lymph ducts,  the tumor cells 
should locally degrade ECM ﬁ rst [1].  In addition, 
the process of ECM degradation is necessary for the 
angiogenesis that is essential for tumor proliferation. 
ECM degradation through MMP is required for the 
migration and proliferation of endocapillary cells that 
is necessary for angiogenesis [2].  There is a close 
correlation between the constituents of ECM and 
tumor cells.  The interaction of tumor cells with 
ECM protein at a receptor level on the cell surface 
induces the production and secretion of proteinase 
(metalloproteinases),  which makes it possible for 
tumor cells to decompose ECM constituents and inﬁ l-
trate to the basal membrane.  The degradation prod-
ucts of ECM (e.g.,  a fragment of ﬁ bronectin) empha-
size the gene expression induction of proteases, 
which results in the formation of the positive feed-
back loop that accelerates the inﬁ ltration and prolif-
eration of tumor cells.  Furthermore,  the isolation of 
growth factors accompanied by ECM degradation 
promotes the proliferation of tumor cells [12]. 
Proteinases which are thought to play a central role 
in this ECM degradation are MMPs,  and Type IV 
collagenase (gelatinase A ＝ MMP-2,  gelatinase 
B ＝ MMP-9) in particular,  which speciﬁ cally 
degrades Type IV collagen has a close correlation 
with the inﬁ ltration and metastasis of tumors.  Each 
MMP is secreted as an inactive pro-form,  when gene 
expression is induced by cytokines or growth factors. 
The pro-form becomes an active form when propep-
tide is removed through the action of proteinases. 
These MMPs are controlled by speciﬁ c inhibitors, 
TIMPs [4].  The blood TIMP concentrations in 
healthy subjects can be quantitated by a Sandwich 
immunoassay using antibodies.  The blood TIMP-1 
and TIMP-2 concentrations have been measured at 
about 170 ng/ml [13] and 56 ng/ml [14],  respec-
tively,  and are present in body ﬂ uids other than 
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Fig. 5　　MVC by treatment schedules was measured in the 
rh-TIMP-1 and control groups.  With Schedule 3,  the MVC levels 
were signiﬁ cantly lower in the rh-TIMP-1 group than in the control 
group.  Based on this result,  it was conﬁ rmed that TIMP-1 had an 
eﬀ ect on microvessels formation,  and that the timing of TIMP-1 
administration greatly enhanced this eﬀ ect (＊ :  ＜ 0.01 vs. 
control).
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Fig. 6　　The inﬂ uence of rh-TIMP-1 (10 ng/ml) on the cell 
proliferation of HT29 was investigated in vitro.  There was no 
remarkable diﬀ erence in cell proliferation between the control 
(TIMP-1 (－)) and rh-TIMP-1 (TIMP-1 (＋)) groups for 24ﾝ72 h after 
rh-TIMP-1 administration.  The inﬂ uence of rh-TIMP-1 with 
changing concentrations was investigated,  but no diﬀ erences 
between the 2 groups was observed (data not shown).
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blood.  In addition,  they are reported to be secreted 
in normal cells including ﬁ broblasts  [17],  endothe-
lial cells  [18] and vascular smooth-muscle cells [19]. 
Four subtypes of TIMPs [20ﾝ23] have been known, 
and each controls the activity of MMPs.  TIMP-1 
speciﬁ cally binds to progelatinase B (pro MMP-9), 
which is a pro-form of gelatinase B (MMP-9),  and 
strongly inhibits the transformation to gelatinase B 
[24].  The inﬂ uence of TIMP-1 on tumor cells has 
been conﬁ rmed by various studies.  In an in vitro 
experiment using the reconstructed basal membrane 
of matrigel,  it was reported that the inﬁ ltration abil-
ity of metastatic tumor cells is inhibited by TIMPs 
[24].  In an in vivo experimental system,  Khokha et 
al.  [25] reported that tumor formation is observed 
when the antisence TIMP-1 gene is introduced to 
nonneoplastic Swiss 3T3 cells and the clone that 
inhibits the TIMP-1 gene expression is selectively 
implanted in nude mice.  However,  some investigators 
have conﬁ rmed the eﬀ ect of TIMPs by introducing 
the TIMP gene to the metastatic tumor cell strain 
and compellingly producing TIMPs.  When the 
TIMP-1 gene was introduced to the mouse melanoma 
cell line,  B16-F10,  by Khokha et al.  [7],  and to the 
human unspecialized gastric cancer stain by Tsuchiya 
et al.  [26],  the metastatic capability of these cells 
was reported to clearly decrease.  It was reported 
that the repeated administration of TIPM-1 to ani-
mals after the implantation of the metastatic tumor 
cell line can inhibit metastasis in vivo [27].  In con-
trast,  Yamauchi et al.  [28] performed an experiment 
to inhibit hepatic metastasis using the gastric cancer 
cell line,  and concluded that the intraperitoneal 
injection of rh-TIMP-1 is less eﬃ  cacious than intro-
duction of the TIMP-1 gene.  They suggest the rea-
son for this is that the blood half-life of rh-TIMP-1 
is short and an eﬀ ective concentration cannot be 
maintained without repeated administration. 
Furthermore,  the suppressive eﬀ ect of TIMP-1 on 
microvessels formation,  as well as on tumor prolifer-
ation,  has been reported.  Johnson et al.   [6] and 
Ikenaka et al.   [29] investigated the suppressive 
eﬀ ect of TIMP-1 on tumor proliferation in vivo and 
in vitro,  and suggested that this eﬀ ect is ascribed to 
the suppression of angiogenesis by TIMP-1.
　　In the present study,  we investigated the suppres-
sive eﬀ ect of TIMP-1,  which is a speciﬁ c inhibitor 
of MMP-9,  and found,  through observation of tumor 
diameters over time and evaluation of immunohisto-
chemical staining,  that TIMP-1 had a suﬃ  cient sup-
pressive eﬀ ect on tumor proliferation.  When TIMP-1 
was administered from the very early stage of tumor 
formation,  as with Schedule 3,  the suppressive 
eﬀ ect on angiogenesis,  in addition to tumor prolifera-
tion,  could be conﬁ rmed.  The results of a cell prolif-
eration assay showed no cytotoxic eﬀ ect of TIMP-1 
on HT29.  Therefore,  the suppressive eﬀ ect on 
tumor proliferation might result from the suppres-
sion of angiogenesis by TIMP-1.  However,  the sup-
pressive eﬀ ect of TIMP-1 on tumor proliferation was 
hardly observed when the treatment was initiated 
after the tumor had grown to some extent,  as with 
Schedule 1.  This suggested that the suppressive 
eﬀ ect of TIMP-1 on angiogenesis was not produced 
when the microvessels were formed on some level in 
the regions around tissues.  In the present study,  in 
consideration of the blood half-life of rh-TIMP-1, 
intraperitoneal injection was performed twice a day 
(every 12 h).  When the tumor diameters were com-
pared,  the suppressive eﬀ ect of tumor proliferation 
was observed clearly with Schedule 3,  and partially 
with Schedule 2.  We did not perform the experiment 
using methods other than regularly prescribed medi-
cation,  but the everyday medication was still thought 
to be the most eﬀ ective administration method.  When 
rh-TIMP-1 is used in clinical practice,  the adminis-
tration methods,  manufacturing cost and side eﬀ ects 
should be considered.
　　When systemic administration is performed,  as 
shown in our study,  repeated administration of a 
large amount of TIMP-1 is required to maintain an 
eﬀ ective blood concentration,  and the cost,  under 
present circumstances,  can be enormous.  Further-
more,  in systemic administration,  TIMP-1 acts on 
regions other than the local tumor and given this, 
side eﬀ ects are unavoidable.  There have been previ-
ous attempts to use TIMPs in clinical practice based 
on the results of basic experiments in the US,  but it 
was concluded to be diﬃ  cult to apply TIMPs in a 
clinical setting [30] due to diﬃ  culty in accomplishing 
the large-scale manufacturing of TIMPs as well as 
problems with the instability and multifunctionality 
[20] of TIMPs.  These problems might be resolved 
when large-scale,  low-cost manufacturing of TIMPs 
can be realized by the improvement of recombinant 
DNA techniques.  If improvement of the drug deliv-
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ery system (DDS) leads to localization of TIMPs on 
the tumor itself,  the dosage can be reduced and side 
eﬀ ects suppressed.  Liu et al.  [31] suggested that a 
complex composed of an antitumor agent and antitu-
mor antibody is eﬀ ective in animals,  and Yamaguchi 
et al.  [32] indicated that a complex composed of a 
human colon cancer monoclonal antibody and a 
Neocarzinostatin is useful in clinical study.  If these 
methods can be applied,  a good treatment eﬀ ect from 
the locally administration of rh-TIMP-1 can be 
expected.  On the other hand,  other than systemic 
administration,  TIMP-1 is applied to the treatment 
by the method of introduction to local tumor and 
overexpression of TIMP-1 gene.  The suppressive 
eﬀ ect of this method on tumor proliferation and 
metastasis has been conﬁ rmed in many basic experi-
ments [28,  32ﾝ35].  In Japan,  the clinical applica-
tions of gene therapy using virus vectors in lung [36] 
and renal [37] cancer has been approved and practi-
cally performed.  This indicates that it is not techni-
cally diﬃ  cult to introduce the TIMP-1 gene to living 
bodies.  The method of injecting rh-TIMP-1 directly 
to the region adjacent to the tumor (intratumoral 
injection) should also be considered,  and its eﬀ ect 
should be conﬁ rmed in vivo in the future.
　　In the present study,  it could be conﬁ rmed that 
the eﬀ ects of rh-TIMP-1 greatly diﬀ ered depending 
on the timing of administration.  The eﬀ ect of 
rh-TIMP-1 on tumor contraction could not be con-
ﬁ rmed.  However,  a slowing down of the proliferation 
rate was observed more in the rh-TIMP-1 group than 
in the control group.  To maximize the eﬀ ect of 
rh-TIMP-1,  it might be necessary to start adminis-
trating it starting when the tumor is minute in size. 
Therefore,  in clinical practice,  the treatment eﬀ ect 
of rh-TIMP-1 could be maximized if it is used after 
shrinkage of the primary focus is obtained by surgi-
cal resection,  or by successful chemotherapy and 
radiotherapy.  Furthermore,  the results of our study 
reproduced the tumor dormant state [38ﾝ39],  in 
which the tumor tissues were not shrunk,  but their 
proliferation was suppressed.  Takahashi et al.  [40] 
reported no correlation between the tumor shrinkage 
eﬀ ect of chemotherapy and the life-prolonging period, 
and tumor shrinkage is not necessary for extension of 
the survival time.  They suggested that the longer a 
tumor remains dormant,  the longer the survival time 
will be.  In addition,  Nemunaitis et al.  [41] per-
formed a clinical study using Marimastat which is 
one of the synthetic MMP inhibitors,  and reported 
that tumor shrinkage is not indispensable for the pro-
longation of survival time and that signiﬁ cant prolon-
gation is observed in patients whose tumor prolifera-
tion has been suppressed.  We expect MMP inhibi-
tors to inhibit,  even indirectly,  the proliferation and 
metastasis of tumor cells,  and to maintain the state 
of coexistence of tumor and recipient (so called 
tumor dormancy) as long as possible even though the 
tumor tissues have not shrunk.  If quality of life can 
be improved and survival time can be prolonged in 
tumorbearing patients,  MMP inhibitors including 
rh-TIMP-1 might have great clinical signiﬁ cance. 
The results of our study showed that rh-TIMP-1 was 
an agent with the potential to be applied in clinical 
settings as an MMP inhibitor.  However,  there were 
several problems with rh-TIMP-1 that need to be 
solved in further studies.
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